Please do not leave this page until complete. This can take a few moments.
Just six weeks after raising $2.35 million in a public offering, a Shelton-based biotechnology company faces delisting from The Nasdaq Stock Market.
The state’s bioscience industry was celebrating Wednesday after lawmakers approved a $55.8 billion, two-year budget that includes expanding the state’s research and development tax credit.
As the CEO of BioCT, I have the privilege every day of advancing and promoting Connecticut’s vibrant life sciences industry. A core part of our mission is to enable talent and companies to come, stay here and grow here.
Bactana Corp., a biotech startup headquartered at UConn’s Technology Incubation Program in Farmington, announced Tuesday it has agreed to be acquired by a global manufacturer.
New Haven-based biotech company Arvinas Inc. announced Thursday that it’s cutting 131 employees, or about a third of its workforce.
GeneDx, a Stamford-based genomic testing firm formerly known as Sema4, has agreed to acquire California-based genomics software company Fabric Genomics for up to $51 million.
Rallybio, a New Haven-based biotechnology firm, said Tuesday it has discontinued development of a therapy intended to prevent a rare immune disorder in fetuses and newborns.
Five months after being granted a reprieve from b
Pass-through business entities with research and development expenses would receive a tax credit under a bill being considered by state lawmakers.
BioXcel Therapeutics Inc., a New Haven-based biopharmaceutical company, said it has raised $14 million from a registered direct offering.
Just three weeks after executing a 1-for-16 reverse stock split of its common stock, New Haven-based biopharmaceutical company BioXcel Therapeutics Inc. on Friday announced it has avoided being delisted from the Nasdaq stock market.
Rallybio, a New Haven-based biotechnology firm, notified federal regulators this week that it faces delisting from the Nasdaq Stock Market.
When Gov. Ned Lamont addressed BioCT’s 2025 legislative breakfast on Jan. 27 in New Haven, his keynote address included a surprise.
The state’s bioscience sector is a lot like that box of chocolates in the film “Forrest Gump” — you never know what you’re going to get. Several state-based companies have recently suffered significant financial woes:
Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and cancer, is in “advanced talks” to be acquired by Germany’s Merck, according to Reuters.
Connecticut and 21 other states jointly sued the federal government on Monday over the administration’s move to slash funding provided to research institutions through the National Institutes of Health.